Boehringer Ingelheim Report Results of BI 695501 in P-III Trial for Patients with Crohn's Disease
Shots:
- The P-III study involves assessing BI 695501 vs Abbvie’s Humira in 147 patients with mod. to sev. CD that were either TNF naïve or prior treated with infliximab
- The P-III study results demonstrated non-inferior efficacy and similar safety profile to the reference product- met its 1Eps i.e- CDAI response @4wks. (89.7% vs 94.4%); infection rates (23.6% vs 22.7%); safety was similar b/w the group with no new safety signals
- BI 695501 is biosimilar referencing AbbVie’s Humira- approved by the US FDA and EMA in 2017 as Cyltezo for multiple chronic inflammatory diseases
Click here Click here to read full press release/ article | Ref: empr- clinical trials | Image: Signbox
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com